Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.68 |
| ▸ | THRA | P10827 | 6/20 | 0.68 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062424 | 0.83 | THRA (0.48) | THRBTHRAALDH1A1RARARARB | |
| SCHEMBL4890901 | 0.82 | THRB (0.69) | THRBTHRAPLA2G4BALDH1A1HPGD | |
| SCHEMBL4890007 | 0.81 | THRB (1.00) | THRBTHRAPLA2G4BALDH1A1HPGD | |
| SCHEMBL17468145 | 0.80 | PLA2G2A (0.54) | THRBTHRAPLA2G4BRARARARB | |
| SCHEMBL13242466 | 0.80 | THRA (0.41) | THRBTHRARARARARB | |
| SCHEMBL12056221 | 0.79 | FFAR4 (0.47) | THRBTHRARARARARBFFAR4 | |
| SCHEMBL4892271 | 0.78 | THRB (0.64) | THRBTHRAPLA2G4BALDH1A1HPGD | |
| SCHEMBL14097975 | 0.78 | THRB (0.64) | THRBTHRAPLA2G4BALDH1A1HPGD | |
| SCHEMBL2126253 | 0.78 | THRB (0.46) | THRBTHRAALDH1A1 | |
| SCHEMBL13242468 | 0.77 | GRIN2D (0.40) | THRBTHRARARARARBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427435-B1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2017-06-14 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9120756-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20150011592-A9 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20140142143-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| WO-2010127856-A1 | SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | THRB 1245/4885THRA 773/4885PLA2G4B 3528/4885 |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | THRB 1305/4885THRA 686/4885PLA2G4B 3249/4885 |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | THRB 1305/4885THRA 686/4885PLA2G4B 3249/4885 |
| US-20150011592-A9 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | THRB 1245/4885THRA 773/4885PLA2G4B 3528/4885 |
| US-20140142143-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | THRB 1245/4885THRA 773/4885PLA2G4B 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.